Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | +13.64% | -6.25% | +31.58% |
05-30 | NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 | CI |
05-02 | NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
- Stock Market
- Equities
- NXTC Stock
- News NextCure, Inc.